HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) rose more than 7% in the midday trading session, with the estimated annual net profit expected to increase more than four times year-on-year. The heavyweight collaboration project is progressing smoothly.
Bai Ao Sai Tu-B (02315) rose more than 7% during trading hours, at the time of writing, up 5.9% to HKD 57.45, with a turnover of HKD 337.277 million.
Biocytogen Pharmaceuticals-B(02315) rose over 7% in intraday trading, and as of the time of writing, it has increased by 5.9% to HK$57.45, with a turnover of HK$33.7277 million.
In terms of news, Biocytogen Pharmaceuticals previously released its 2025 performance report, with preliminary accounting data showing that the company's revenue in 2025 was approximately RMB 1.379 billion, achieving a net profit of RMB 173 million attributable to the parent company, representing year-on-year growth of 40.63% and 416.37% respectively. In addition, the company's authorized IDEAYA's B7H3/PTK7 ADC candidate drug IDE034 has completed the enrollment of the first patient in its Phase 1 clinical trial, with IDEAYA set to pay the company a $5 million milestone payment.
Related Articles
MIN XIN HOLD (00222) announces profit growth, with estimated annual net profit attributable to shareholders of approximately HK$1.1 billion to HK$1.3 billion, a year-on-year increase of about 25% to 48%.
CHINA EB LTD (00165) completes the issuance of RMB 2 billion medium-term notes.
Ming Liang Holdings (08152) released a profit announcement, expecting a post-tax profit of approximately HKD 8 to 9 million for the year 2025, turning from a loss to a profit year-on-year.
MIN XIN HOLD (00222) announces profit growth, with estimated annual net profit attributable to shareholders of approximately HK$1.1 billion to HK$1.3 billion, a year-on-year increase of about 25% to 48%.
CHINA EB LTD (00165) completes the issuance of RMB 2 billion medium-term notes.
Ming Liang Holdings (08152) released a profit announcement, expecting a post-tax profit of approximately HKD 8 to 9 million for the year 2025, turning from a loss to a profit year-on-year.
